NewcelX Ltd. Announces $1.35 Million Private Placement to Advance Type 1 Diabetes Program NCEL-101

On April 1, 2026, NewcelX Ltd. entered into definitive securities purchase agreements for a private placement offering expected to yield gross proceeds of approximately $1.35 million. The company is selling 490,907 common shares (or pre-funded warrants) at $2.75 per share, along with common warrants to purchase up to 687,270 ordinary shares at an exercise price of $3.025 per share. If the warrants are exercised in full for cash, the company could receive an additional $2.1 million. NewcelX intends to utilize the net proceeds, combined with its existing $25 million equity line, to advance its lead program, NCEL-101, for the treatment of Type 1 Diabetes in collaboration with Eledon Pharmaceuticals. Funds will also support the broader development pipeline and general corporate purposes. The offering is scheduled to close around April 15, 2026. As part of the agreement, NewcelX has committed to filing a resale registration statement for the securities within 45 days of the agreement date.